Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 941-950 Newer>

ifeminists December 30, 2003 Katie Allison Granju	The Milky Way of Doing Business How has the American Academy of Pediatrics been influenced by the $3 billion U.S. infant formula industry?
The Motley Fool December 30, 2003 Arash Mostaghimi	Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers.
The Motley Fool December 29, 2003 Alyce Lomax	Lilly's Symbyax Gets Green Light Prozac has a new lease on life. The Food and Drug Administration recently approved Eli Lilly's well-known antidepressant in combination with Zyprexa for the treatment of bipolar depression.
The Motley Fool December 23, 2003 Arash Mostaghimi	The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio?
The Motley Fool December 22, 2003 Alyce Lomax	Losing Faith in Inspire Delay for its dry-eye treatment leaves investors uninspired.
The Motley Fool December 22, 2003 Jeff Hwang	Pfizer Stuffs Its Pipeline Pfizer extends its reach in cardiovascular disease with Esperion Therapeutics.
Bio-IT World December 15, 2003 Mark D. Uehling	Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials.
Bio-IT World December 15, 2003 Kline & Greenhalgh	When Patents Persist What if that patent you're paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible?
Bio-IT World December 15, 2003 Henry & Vertinsky	The Hidden Costs of 'Free' Software Open-source software may be gaining ground in academic and government circles, but biotech users need to be aware of licensing pitfalls.
Bio-IT World December 15, 2003 Mark D. Uehling	A Diamond in the Desert Drawn by impressive research budgets, talent, and 'serendipity,' a prodigal son returns to build a biotech oasis in Phoenix.
<Older 941-950 Newer> Return to current articles.